Brief: Genmab Shares Encouraging Early-Stage Data On Epcoritamab For RT Patients

Genmab A/S

09/12/2025 07:49

Dec 9 (Reuters) - Genmab A/S GMAB.CO:

ANNOUNCES NEW DATA FROM PHASE 1B/2 EPCORE® CLL-1 HIGHLIGHTING POTENTIAL OF EPCORITAMAB AS MONOTHERAPY AND IN COMBINATION FOR PATIENTS WITH RICHTER TRANSFORMATION (RT)

ADDITIONAL EARLY DATA SHOW PROMISING EFFICACY OF EPCORITAMAB COMBINATION REGIMENS IN PATIENTS WITH RT

SAYS RESULTS UNDERSCORE THE POTENTIAL OF EPCORITAMAB AS A VERSATILE THERAPY FOR A BROAD RANGE OF B-CELL MALIGNANCIES

Source text: ID:nGNE10hW8g

Further company coverage: GMAB.CO

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))